# The Efficacy and Safety of PEG-rhG-CSF in Preventing Chemotherapy-induced Neutropenia

> **NCT02761460** · PHASE3 · UNKNOWN · sponsor: **wang shusen** · enrollment: 338 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** PEG-rhG-CSF

## Key facts

- **NCT ID:** NCT02761460
- **Lead sponsor:** wang shusen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-05-04
- **Primary completion:** 2018-04
- **Final completion:** 2018-12
- **Target enrollment:** 338 (ESTIMATED)
- **Last updated:** 2017-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02761460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02761460, "The Efficacy and Safety of PEG-rhG-CSF in Preventing Chemotherapy-induced Neutropenia". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT02761460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*